Stocks · News reference
8-K filing — TruBridge, Inc. (TBRG)
Filed: 2026-07-09 AccNo: 0001193125-26-299668 Size: 290 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Halper Sadeh LLC is Investigating Whether DAN, ROKU, TBRG, AFBI are Obtaining Fair Deals for their Shareholders
Investor rights law firm Halper Sadeh LLC is investigating four proposed mergers and acquisitions to determine if shareholders are receiving fair deals. The investigations focus on Dana Incorporated's sale to Eaton Corporation, Roku's acquisition by Fox Corporation, TruBridge's sale to Inventurus Knowledge Solutions, and Affinity Bancshares' merger with Fidelity BancShares. The firm is examining potential securities law violations and fiduciary duty breaches, particularly regarding insider benefits and terms that may limit competing offers.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.